JP2019038829A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019038829A5 JP2019038829A5 JP2018202024A JP2018202024A JP2019038829A5 JP 2019038829 A5 JP2019038829 A5 JP 2019038829A5 JP 2018202024 A JP2018202024 A JP 2018202024A JP 2018202024 A JP2018202024 A JP 2018202024A JP 2019038829 A5 JP2019038829 A5 JP 2019038829A5
- Authority
- JP
- Japan
- Prior art keywords
- represented
- formula
- compound
- disease
- neurodegenerative disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 14
- 230000004770 neurodegeneration Effects 0.000 claims 8
- 208000015122 neurodegenerative disease Diseases 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 6
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 4
- 208000027747 Kennedy disease Diseases 0.000 claims 4
- 208000029402 Bulbospinal muscular atrophy Diseases 0.000 claims 2
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 239000003098 androgen Substances 0.000 claims 2
- -1 purine skeleton compound Chemical class 0.000 claims 2
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- UYODNJZBUUEXPC-UHFFFAOYSA-N 9-[2-(2,2-dimethylpropylamino)ethyl]-8-[(6-iodo-1,3-benzodioxol-5-yl)sulfanyl]purin-6-amine Chemical compound N1=CN=C2N(CCNCC(C)(C)C)C(SC=3C(=CC=4OCOC=4C=3)I)=NC2=C1N UYODNJZBUUEXPC-UHFFFAOYSA-N 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000027089 Parkinsonian disease Diseases 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80642706P | 2006-06-30 | 2006-06-30 | |
| US60/806,427 | 2006-06-30 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017110721A Division JP6427227B2 (ja) | 2006-06-30 | 2017-06-05 | Ｈｓｐ９０の阻害による神経変性疾患の処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019038829A JP2019038829A (ja) | 2019-03-14 |
| JP2019038829A5 true JP2019038829A5 (enExample) | 2019-05-09 |
| JP6585266B2 JP6585266B2 (ja) | 2019-10-02 |
Family
ID=38895418
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009518602A Expired - Fee Related JP5599610B2 (ja) | 2006-06-30 | 2007-07-02 | Ｈｓｐ９０の阻害による神経変性疾患の処置 |
| JP2013058040A Expired - Fee Related JP5824698B2 (ja) | 2006-06-30 | 2013-03-21 | Ｈｓｐ９０の阻害による神経変性疾患の処置 |
| JP2015174609A Pending JP2016028063A (ja) | 2006-06-30 | 2015-09-04 | Ｈｓｐ９０の阻害による神経変性疾患の処置 |
| JP2017110721A Expired - Fee Related JP6427227B2 (ja) | 2006-06-30 | 2017-06-05 | Ｈｓｐ９０の阻害による神経変性疾患の処置 |
| JP2018202024A Expired - Fee Related JP6585266B2 (ja) | 2006-06-30 | 2018-10-26 | Ｈｓｐ９０の阻害による神経変性疾患の処置 |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009518602A Expired - Fee Related JP5599610B2 (ja) | 2006-06-30 | 2007-07-02 | Ｈｓｐ９０の阻害による神経変性疾患の処置 |
| JP2013058040A Expired - Fee Related JP5824698B2 (ja) | 2006-06-30 | 2013-03-21 | Ｈｓｐ９０の阻害による神経変性疾患の処置 |
| JP2015174609A Pending JP2016028063A (ja) | 2006-06-30 | 2015-09-04 | Ｈｓｐ９０の阻害による神経変性疾患の処置 |
| JP2017110721A Expired - Fee Related JP6427227B2 (ja) | 2006-06-30 | 2017-06-05 | Ｈｓｐ９０の阻害による神経変性疾患の処置 |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US10336757B2 (enExample) |
| EP (2) | EP3305297A1 (enExample) |
| JP (5) | JP5599610B2 (enExample) |
| AU (1) | AU2007269144B2 (enExample) |
| CA (1) | CA2656202C (enExample) |
| DK (1) | DK2034839T3 (enExample) |
| ES (1) | ES2645095T3 (enExample) |
| WO (1) | WO2008005937A2 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9403828B2 (en) | 2005-02-01 | 2016-08-02 | Sloan-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| WO2006084030A2 (en) * | 2005-02-01 | 2006-08-10 | Sloan-Kettering Institute For Cancer Research | Small-molecule hsp90 inhibitors |
| CN101490052B (zh) * | 2006-05-12 | 2012-08-08 | 美瑞德生物工程公司 | 治疗性化合物及其在癌症中的用途 |
| JP5599610B2 (ja) * | 2006-06-30 | 2014-10-01 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | Ｈｓｐ９０の阻害による神経変性疾患の処置 |
| BRPI0808301B1 (pt) | 2007-03-20 | 2022-05-03 | Curis, Inc | Composto e composição farmacêutica |
| CA2705579A1 (en) * | 2007-11-14 | 2009-05-22 | Myriad Pharmaceuticals, Inc. | Therapeutic compounds and their use in treating diseases and disorders |
| US20090258869A1 (en) * | 2008-02-08 | 2009-10-15 | The Regents Of The University Of California | Methods and compounds for treatment or prevention of substance-related disorders |
| EP2484371B1 (en) | 2008-06-26 | 2014-12-17 | Orphazyme APS | Use of Hsp70 as a regulator of enzymatic activity |
| JP2012529535A (ja) | 2009-06-12 | 2012-11-22 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼモジュレーターとして有用なニコチンアミド化合物 |
| WO2011044394A1 (en) | 2009-10-07 | 2011-04-14 | Sloan-Kettering Institute For Cancer Research | Purine derivatives useful as hsp90 inhibitors |
| AU2013204109B2 (en) * | 2009-10-07 | 2016-05-05 | Sloan-Kettering Institute For Cancer Research | Purine derivatives useful as hsp90 inhibitors |
| RU2013125923A (ru) | 2010-11-30 | 2015-01-10 | Орфазиме Апс | СПОСОБЫ УВЕЛИЧЕНИЯ ВНУТРИКЛЕТОЧНОЙ АКТИВНОСТИ Hsp70 |
| EP2694506B1 (en) | 2011-04-05 | 2017-09-20 | Sloan-kettering Institute For Cancer Research | Hsp90 inhibitors |
| EP2694505B1 (en) * | 2011-04-05 | 2022-04-27 | Sloan-kettering Institute For Cancer Research | Hsp90 inhibitors |
| CA2841069C (en) | 2011-07-08 | 2021-11-23 | Sloan-Kettering Institute For Cancer Research | Uses of labeled hsp90 inhibitors |
| US20140079636A1 (en) | 2012-04-16 | 2014-03-20 | Dinesh U. Chimmanamada | Targeted therapeutics |
| WO2014025395A1 (en) * | 2012-08-06 | 2014-02-13 | Duke University | Compounds and methods for targeting hsp90 |
| RU2644769C2 (ru) | 2013-01-23 | 2018-02-14 | Астразенека Аб | Химические соединения |
| AU2014228822A1 (en) | 2013-03-15 | 2015-10-01 | Memorial Sloan-Kettering Cancer Center | HSP90-targeted cardiac imaging and therapy |
| EA201690406A1 (ru) | 2013-08-16 | 2016-08-31 | Мемориал Слоун-Кеттеринг Кэнсэ Сентр | Селективные ингибиторы grp94 и способы их применения |
| EP3035938B1 (en) | 2013-09-10 | 2020-08-19 | Madrigal Pharmaceuticals, Inc. | Targeted therapeutics |
| WO2015066053A2 (en) | 2013-10-28 | 2015-05-07 | Synta Pharmaceuticals Corp. | Targeted therapeutics |
| AU2014386214B2 (en) | 2013-12-23 | 2020-05-21 | Memorial Sloan-Kettering Cancer Center | Methods and reagents for radiolabeling |
| WO2015116774A1 (en) | 2014-01-29 | 2015-08-06 | Synta Pharmaceuticals Corp. | Targeted therapeutics |
| CN106456795A (zh) | 2014-03-03 | 2017-02-22 | 辛塔医药品有限公司 | 靶向治疗学 |
| EP3131586A4 (en) | 2014-03-18 | 2017-10-25 | Madrigal Pharmaceuticals, Inc. | Targeted therapeutics |
| US10709700B2 (en) | 2014-09-15 | 2020-07-14 | Orphazyme A/S | Arimoclomol formulation |
| BR112017005313A2 (pt) | 2014-09-17 | 2017-12-05 | Memorial Sloan Kettering Cancer Center | formação de imagem e terapia para inflamação e infecção direcionadas por hsp90 |
| US20180280397A1 (en) | 2015-10-05 | 2018-10-04 | Memorial Sloan Kettering Cancer Center | Rational combination therapy for the treatment of cancer |
| EP3442530A1 (en) | 2016-04-13 | 2019-02-20 | Orphazyme A/S | Heat shock proteins and cholesterol homeostasis |
| US11261187B2 (en) | 2016-04-22 | 2022-03-01 | Duke University | Compounds and methods for targeting HSP90 |
| SI3448382T1 (sl) | 2016-04-29 | 2021-03-31 | Orphazyme A/S, c/o COBIS A/S | Arimoclomol za zdravljenje motenj, povezanih z glukocerebrozidazo |
| EP3680241A1 (en) | 2017-03-20 | 2020-07-15 | Forma Therapeutics, Inc. | Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators |
| AU2018257901A1 (en) * | 2017-04-24 | 2019-11-14 | Samus Therapeutics, Inc. | Hsp90 inhibitor oral formulations and related methods |
| JP2020524156A (ja) | 2017-06-20 | 2020-08-13 | マドリガル ファーマシューティカルズ インコーポレイテッドＭａｄｒｉｇａｌ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 標的治療薬を含む併用療法 |
| JP2020524154A (ja) | 2017-06-20 | 2020-08-13 | マドリガル ファーマシューティカルズ インコーポレイテッドＭａｄｒｉｇａｌ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 標的治療薬 |
| AU2018290288A1 (en) * | 2017-06-23 | 2020-01-16 | Samus Therapeutics, Inc. | Epichaperome inhibitor therapy for traumatic brain injury and sequelae thereof |
| MD3762368T2 (ro) | 2018-03-08 | 2022-07-31 | Incyte Corp | Compuși diol aminopirazină ca inhibitori ai PI3K-Y |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| US10675274B2 (en) | 2018-09-19 | 2020-06-09 | Forma Therapeutics, Inc. | Activating pyruvate kinase R |
| WO2020061255A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| HUE072832T2 (hu) | 2019-09-19 | 2025-12-28 | Novo Nordisk Healthcare Ag | Piruvát kináz R-t (PKR) aktiváló készítmények |
| WO2022106614A1 (en) | 2020-11-19 | 2022-05-27 | Orphazyme A/S | Processes for preparing arimoclomol citrate and intermediates thereof |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998051702A1 (en) | 1997-05-14 | 1998-11-19 | Sloan-Kettering Institute For Cancer Research | Methods and compositions for destruction of selected proteins |
| AU769235B2 (en) | 1999-04-09 | 2004-01-22 | Sloan-Kettering Institute For Cancer Research | Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases |
| AU2002228771B2 (en) | 2000-11-02 | 2007-10-25 | Sloan-Kettering Institute For Cancer Research | Small molecule compositions for binding to HSP90 |
| EP1387678A1 (en) * | 2001-05-03 | 2004-02-11 | Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. | Compounds that inhibit hsp90 and stimulate hsp70 and hsp40, useful in the prevention or treatment of diseases associated with protein aggregation and amyloid formation |
| EP1440072A4 (en) | 2001-10-30 | 2005-02-02 | Conforma Therapeutic Corp | PURINE ANALOGS HAVING HSP90 INHIBITORY ACTIVITY |
| US7553979B2 (en) | 2001-11-09 | 2009-06-30 | Conforma Therapeutics Corporation | HSP90-inhibiting zearalanol compounds and methods of producing and using same |
| AU2003207340A1 (en) | 2002-02-28 | 2003-09-09 | Astrazeneca Ab | 3-cyclyl-5-(nitrogen-containing 5-membered ring) methyl-oxazolidinone derivatives and their use as antibacterial agents |
| WO2004094647A2 (en) | 2003-04-18 | 2004-11-04 | Cytovia, Inc. | Methods of treating diseases responsive to induction of apoptosis and screening assays |
| GB0315111D0 (en) | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
| US20070178537A1 (en) | 2003-06-30 | 2007-08-02 | Sloan-Kettering Institute For Cancer Research | Assays for detection of bioactive compounds that interact with heat shock protein 90 |
| NZ546611A (en) | 2003-09-18 | 2010-02-26 | Conforma Therapeutics Corp | Novel heterocyclic compounds as HSP90-inhibitors |
| WO2006084030A2 (en) | 2005-02-01 | 2006-08-10 | Sloan-Kettering Institute For Cancer Research | Small-molecule hsp90 inhibitors |
| US9403828B2 (en) | 2005-02-01 | 2016-08-02 | Sloan-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| US7358370B2 (en) | 2005-02-25 | 2008-04-15 | Serenex, Inc. | Benzene, pyridine, and pyridazine derivatives |
| WO2006130469A1 (en) * | 2005-05-27 | 2006-12-07 | Oregon Health & Science University | Stimulation of neurite outgrowth by small molecules |
| US20110263693A1 (en) | 2006-03-31 | 2011-10-27 | Dana-Farber Cancer Institute, Inc. | Celastrol, gedunin, and derivatives thereof as hsp90 inhibitors |
| CN101490052B (zh) | 2006-05-12 | 2012-08-08 | 美瑞德生物工程公司 | 治疗性化合物及其在癌症中的用途 |
| JP5599610B2 (ja) * | 2006-06-30 | 2014-10-01 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | Ｈｓｐ９０の阻害による神経変性疾患の処置 |
| WO2008013985A2 (en) | 2006-07-27 | 2008-01-31 | University Of Florida | Use of heat shock activators for tissue regeneration |
| US20080221132A1 (en) | 2006-09-11 | 2008-09-11 | Xiong Cai | Multi-Functional Small Molecules as Anti-Proliferative Agents |
| CL2007002994A1 (es) | 2006-10-19 | 2008-02-08 | Wyeth Corp | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. |
| GB0622084D0 (en) | 2006-11-06 | 2006-12-13 | Chroma Therapeutics Ltd | Inhibitors of HSP90 |
| US8580519B2 (en) | 2006-11-27 | 2013-11-12 | University Of Maryland, Baltimore | Use of plasma HSP90 related to malignancy |
| WO2008115262A2 (en) | 2007-03-20 | 2008-09-25 | Curis, Inc. | Hsp90 inhibitors containing a zinc binding moiety |
| BRPI0808301B1 (pt) | 2007-03-20 | 2022-05-03 | Curis, Inc | Composto e composição farmacêutica |
| EP2183221A1 (en) | 2007-07-12 | 2010-05-12 | Crystax Pharmaceuticals S.L. | New compounds as hsp90 inhibitors |
| WO2009042646A1 (en) | 2007-09-24 | 2009-04-02 | Curis, Inc. | Anti-proliferative agents |
| CA2705579A1 (en) | 2007-11-14 | 2009-05-22 | Myriad Pharmaceuticals, Inc. | Therapeutic compounds and their use in treating diseases and disorders |
| WO2011044394A1 (en) | 2009-10-07 | 2011-04-14 | Sloan-Kettering Institute For Cancer Research | Purine derivatives useful as hsp90 inhibitors |
| EP2694506B1 (en) | 2011-04-05 | 2017-09-20 | Sloan-kettering Institute For Cancer Research | Hsp90 inhibitors |
| EP2694505B1 (en) | 2011-04-05 | 2022-04-27 | Sloan-kettering Institute For Cancer Research | Hsp90 inhibitors |
| EA201690406A1 (ru) | 2013-08-16 | 2016-08-31 | Мемориал Слоун-Кеттеринг Кэнсэ Сентр | Селективные ингибиторы grp94 и способы их применения |
-
2007
- 2007-07-02 JP JP2009518602A patent/JP5599610B2/ja not_active Expired - Fee Related
- 2007-07-02 DK DK07812557.2T patent/DK2034839T3/en active
- 2007-07-02 EP EP17177927.5A patent/EP3305297A1/en not_active Withdrawn
- 2007-07-02 ES ES07812557.2T patent/ES2645095T3/es active Active
- 2007-07-02 CA CA2656202A patent/CA2656202C/en active Active
- 2007-07-02 US US12/307,063 patent/US10336757B2/en active Active
- 2007-07-02 EP EP07812557.2A patent/EP2034839B1/en active Active
- 2007-07-02 AU AU2007269144A patent/AU2007269144B2/en not_active Ceased
- 2007-07-02 WO PCT/US2007/072671 patent/WO2008005937A2/en not_active Ceased
-
2013
- 2013-03-21 JP JP2013058040A patent/JP5824698B2/ja not_active Expired - Fee Related
-
2014
- 2014-09-10 US US14/482,628 patent/US20140378452A1/en not_active Abandoned
-
2015
- 2015-09-04 JP JP2015174609A patent/JP2016028063A/ja active Pending
-
2017
- 2017-06-05 JP JP2017110721A patent/JP6427227B2/ja not_active Expired - Fee Related
-
2018
- 2018-10-26 JP JP2018202024A patent/JP6585266B2/ja not_active Expired - Fee Related
-
2019
- 2019-04-30 US US16/398,650 patent/US20190389864A1/en not_active Abandoned
-
2021
- 2021-10-15 US US17/502,563 patent/US20230060990A1/en not_active Abandoned
-
2023
- 2023-05-26 US US18/202,704 patent/US12473288B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019524822A5 (enExample) | ||
| JP2018150331A5 (enExample) | ||
| JOP20230235A1 (ar) | عقاقير أولية جديدة من الكاتيكولامين للاستخدام في علاج مرض باركنسون | |
| EP4681777A3 (en) | Prodrugs of ketamine, compositions and uses thereof | |
| JP2022515293A5 (enExample) | ||
| JP2014500861A5 (enExample) | ||
| JP2018518537A5 (enExample) | ||
| JP2017105793A5 (enExample) | ||
| JP2016534063A5 (enExample) | ||
| JP2019516739A5 (enExample) | ||
| JP2024516371A5 (enExample) | ||
| JP2020097577A5 (enExample) | ||
| JP2012255002A5 (enExample) | ||
| JP2016537432A5 (enExample) | ||
| JP2019524865A5 (enExample) | ||
| JP2009504748A5 (enExample) | ||
| JP2016537338A5 (enExample) | ||
| MX2011011477A (es) | Derivados de isoxazol-piridazina. | |
| MA38079A1 (fr) | Composés de 2-phényl-5-hétérocyclyl-tétrahydro-2h-pyran-3-amine destinés à être utilisés dans le traitement du diabète et de ses troubles associés | |
| JP2017511339A5 (enExample) | ||
| JP2017511377A5 (enExample) | ||
| JP2014530818A5 (enExample) | ||
| JP2022539152A5 (enExample) | ||
| JP2011046708A5 (enExample) | ||
| JP2018145180A5 (enExample) |